Discovery of novel anti-diabetic drugs by targeting lipid metabolism

Xiu Zhou, Jun Xu, Yuguang Shi, Ji Ming Ye

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Accumulation of toxic lipids is the most common etiology of insulin resistance in type 2 diabetes and associated metabolic disorders such as obesity and non-alcoholic fatty liver disease. Understanding of the underlying mechanisms has revealed various opportunities to target key regulators in lipid metabolic pathways for the treatment of metabolic diseases. Here, we review the discovery and development of potential anti-diabetic drugs with primary effects on cellular targets leading to reductions of intracellular lipids in key organs. We will particularly focus on AMPK, SIRT1, PGC-1α, SREBP-1c, ChREBP, ACC, PPARs and HSPs which either stimulate in fatty acid oxidation (energy expenditure) or inhibit de novo lipogenesis.

Original languageEnglish (US)
Pages (from-to)1372-1380
Number of pages9
JournalCurrent Drug Targets
Volume16
Issue number12
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

Drug Delivery Systems
Lipid Metabolism
Lipids
Pharmaceutical Preparations
Sterol Regulatory Element Binding Protein 1
Lipogenesis
Peroxisome Proliferator-Activated Receptors
AMP-Activated Protein Kinases
Poisons
Metabolic Diseases
Medical problems
Metabolic Networks and Pathways
Liver
Type 2 Diabetes Mellitus
Energy Metabolism
Insulin Resistance
Fatty Acids
Obesity
Insulin
Oxidation

Keywords

  • Anti-diabetic drug targets
  • Drug discovery
  • Insulin resistance
  • Lipid metabolism

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Discovery of novel anti-diabetic drugs by targeting lipid metabolism. / Zhou, Xiu; Xu, Jun; Shi, Yuguang; Ye, Ji Ming.

In: Current Drug Targets, Vol. 16, No. 12, 01.11.2015, p. 1372-1380.

Research output: Contribution to journalArticle

Zhou, Xiu ; Xu, Jun ; Shi, Yuguang ; Ye, Ji Ming. / Discovery of novel anti-diabetic drugs by targeting lipid metabolism. In: Current Drug Targets. 2015 ; Vol. 16, No. 12. pp. 1372-1380.
@article{953ad346d0d444c6b0a00e6e8a7a0be3,
title = "Discovery of novel anti-diabetic drugs by targeting lipid metabolism",
abstract = "Accumulation of toxic lipids is the most common etiology of insulin resistance in type 2 diabetes and associated metabolic disorders such as obesity and non-alcoholic fatty liver disease. Understanding of the underlying mechanisms has revealed various opportunities to target key regulators in lipid metabolic pathways for the treatment of metabolic diseases. Here, we review the discovery and development of potential anti-diabetic drugs with primary effects on cellular targets leading to reductions of intracellular lipids in key organs. We will particularly focus on AMPK, SIRT1, PGC-1α, SREBP-1c, ChREBP, ACC, PPARs and HSPs which either stimulate in fatty acid oxidation (energy expenditure) or inhibit de novo lipogenesis.",
keywords = "Anti-diabetic drug targets, Drug discovery, Insulin resistance, Lipid metabolism",
author = "Xiu Zhou and Jun Xu and Yuguang Shi and Ye, {Ji Ming}",
year = "2015",
month = "11",
day = "1",
doi = "10.2174/1389450116666150223120829",
language = "English (US)",
volume = "16",
pages = "1372--1380",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Discovery of novel anti-diabetic drugs by targeting lipid metabolism

AU - Zhou, Xiu

AU - Xu, Jun

AU - Shi, Yuguang

AU - Ye, Ji Ming

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Accumulation of toxic lipids is the most common etiology of insulin resistance in type 2 diabetes and associated metabolic disorders such as obesity and non-alcoholic fatty liver disease. Understanding of the underlying mechanisms has revealed various opportunities to target key regulators in lipid metabolic pathways for the treatment of metabolic diseases. Here, we review the discovery and development of potential anti-diabetic drugs with primary effects on cellular targets leading to reductions of intracellular lipids in key organs. We will particularly focus on AMPK, SIRT1, PGC-1α, SREBP-1c, ChREBP, ACC, PPARs and HSPs which either stimulate in fatty acid oxidation (energy expenditure) or inhibit de novo lipogenesis.

AB - Accumulation of toxic lipids is the most common etiology of insulin resistance in type 2 diabetes and associated metabolic disorders such as obesity and non-alcoholic fatty liver disease. Understanding of the underlying mechanisms has revealed various opportunities to target key regulators in lipid metabolic pathways for the treatment of metabolic diseases. Here, we review the discovery and development of potential anti-diabetic drugs with primary effects on cellular targets leading to reductions of intracellular lipids in key organs. We will particularly focus on AMPK, SIRT1, PGC-1α, SREBP-1c, ChREBP, ACC, PPARs and HSPs which either stimulate in fatty acid oxidation (energy expenditure) or inhibit de novo lipogenesis.

KW - Anti-diabetic drug targets

KW - Drug discovery

KW - Insulin resistance

KW - Lipid metabolism

UR - http://www.scopus.com/inward/record.url?scp=84946732224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946732224&partnerID=8YFLogxK

U2 - 10.2174/1389450116666150223120829

DO - 10.2174/1389450116666150223120829

M3 - Article

C2 - 25706109

AN - SCOPUS:84946732224

VL - 16

SP - 1372

EP - 1380

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 12

ER -